Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Apr 16;15:293. doi: 10.1186/s12885-015-1264-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Gillgrass et al.; licensee BioMed Central. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

A comparison of NK cell phenotype in IL-15 TG/MT and MT tumors. Tumors from MT, IL-15 KO/MT and IL-15 TG/MT mice were digested and stained for flow cytometry (only one tumor taken from each mouse). (A) Of CD45+ cells in the tumor, there was a higher proportion of NK1.1+ cells in the IL-15 TG/MT tumors than in the MT or IL-15 KO/MT tumors (n = 10- IL-15 KO/MT, 8- MT or IL-15 TG/MT). (B) In the IL-15 TG/MT tumors, the majority of the NK cells possess the early activation marker CD69. In addition, a higher percentage of NK cells in IL-15 TG/MT tumors possess CD27, a marker of highly cytotoxic NK cells. Lastly, a higher percent of the NK cells in IL-15 TG/MT tumors possess the activation markers NKp46 and NKG2D, as well as perforin (n = 3 to 9). *p < 0.05.